Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To assess the efficacy of single agent AZD9291 compared with standard of care (SoC) Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) therapy as measured by progression free survival (PFS)
Critère d'inclusion
- Locally advanced or metastatic non-small cell lung cancer, not amenable to curative surgery or radiotherapy